PortalPublikationenStudienergebnisse zur Primärtherapie von Kopf-Hals-Tumoren: ...

Studienergebnisse zur Primärtherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2016

Standard

Studienergebnisse zur Primärtherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2016. / Gliese, A; Busch, C-J; Knecht, R.

in: HNO, Jahrgang 64, Nr. 10, 10.2016, S. 717-22.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Gliese, A, Busch, C-J & Knecht, R 2016, 'Studienergebnisse zur Primärtherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2016', HNO, Jg. 64, Nr. 10, S. 717-22. https://doi.org/10.1007/s00106-016-0243-6

APA

Gliese, A., Busch, C-J., & Knecht, R. (2016). Studienergebnisse zur Primärtherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2016. HNO, 64(10), 717-22. https://doi.org/10.1007/s00106-016-0243-6

Vancouver

Gliese A, Busch C-J, Knecht R. Studienergebnisse zur Primärtherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2016. HNO. 2016 Okt;64(10):717-22. https://doi.org/10.1007/s00106-016-0243-6

Bibtex

@article{6aca79ac09364826981ba755acd1a17c,
title = "Studienergebnisse zur Prim{\"a}rtherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2016",
abstract = "At the annual meeting of the American Society of Clinical Oncology (ASCO) 2016, results of current trials dealing with primary therapy for head and neck squamous cell carcinoma (HNSCC) were presented. Current trials investigate in particular therapy regimens for the treatment of locally advanced HNSCC. Concomitant chemoradiotherapy (CRT) remains the standard therapy approach. Current trials focus on sequential chemoradiation with modifications in induction chemotherapy (ICT) or the subsequent CRT schedule. Studies investigating the combination of targeted therapy with the epidermal growth factor receptor (EGFR) antibody cetuximab and concomitant, sequential, or adjuvant therapy were presented. The most important trials are summarized in this article.",
keywords = "English Abstract, Journal Article",
author = "A Gliese and C-J Busch and R Knecht",
year = "2016",
month = oct,
doi = "10.1007/s00106-016-0243-6",
language = "Deutsch",
volume = "64",
pages = "717--22",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "10",

}

RIS

TY - JOUR

T1 - Studienergebnisse zur Primärtherapie von Kopf-Hals-Tumoren: Highlights der ASCO-Jahrestagung 2016

AU - Gliese, A

AU - Busch, C-J

AU - Knecht, R

PY - 2016/10

Y1 - 2016/10

N2 - At the annual meeting of the American Society of Clinical Oncology (ASCO) 2016, results of current trials dealing with primary therapy for head and neck squamous cell carcinoma (HNSCC) were presented. Current trials investigate in particular therapy regimens for the treatment of locally advanced HNSCC. Concomitant chemoradiotherapy (CRT) remains the standard therapy approach. Current trials focus on sequential chemoradiation with modifications in induction chemotherapy (ICT) or the subsequent CRT schedule. Studies investigating the combination of targeted therapy with the epidermal growth factor receptor (EGFR) antibody cetuximab and concomitant, sequential, or adjuvant therapy were presented. The most important trials are summarized in this article.

AB - At the annual meeting of the American Society of Clinical Oncology (ASCO) 2016, results of current trials dealing with primary therapy for head and neck squamous cell carcinoma (HNSCC) were presented. Current trials investigate in particular therapy regimens for the treatment of locally advanced HNSCC. Concomitant chemoradiotherapy (CRT) remains the standard therapy approach. Current trials focus on sequential chemoradiation with modifications in induction chemotherapy (ICT) or the subsequent CRT schedule. Studies investigating the combination of targeted therapy with the epidermal growth factor receptor (EGFR) antibody cetuximab and concomitant, sequential, or adjuvant therapy were presented. The most important trials are summarized in this article.

KW - English Abstract

KW - Journal Article

U2 - 10.1007/s00106-016-0243-6

DO - 10.1007/s00106-016-0243-6

M3 - SCORING: Zeitschriftenaufsatz

C2 - 27624903

VL - 64

SP - 717

EP - 722

JO - HNO

JF - HNO

SN - 0017-6192

IS - 10

ER -